National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$44.69|
|52 Week High||US$42.41|
|52 Week Low||US$59.20|
|1 Month Change||-18.00%|
|3 Month Change||-3.52%|
|1 Year Change||-7.89%|
|3 Year Change||16.99%|
|5 Year Change||180.89%|
|Change since IPO||123.45%|
Recent News & Updates
|NRC||US Healthcare||US Market|
Return vs Industry: NRC underperformed the US Healthcare industry which returned 33% over the past year.
Return vs Market: NRC underperformed the US Market which returned 32.8% over the past year.
Stable Share Price: NRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: NRC's weekly volatility (3%) has been stable over the past year.
About the Company
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools.
National Research Fundamentals Summary
|NRC fundamental statistics|
Is NRC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NRC income statement (TTM)|
|Cost of Revenue||US$49.48m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.41|
|Net Profit Margin||25.64%|
How did NRC perform over the long term?See historical performance and comparison
1.1%Current Dividend Yield
Does NRC pay a reliable dividends?See NRC dividend history and benchmarks
|National Research dividend dates|
|Ex Dividend Date||Sep 29 2021|
|Dividend Pay Date||Oct 15 2021|
|Days until Ex dividend||1 day|
|Days until Dividend pay date||17 days|
Does NRC pay a reliable dividends?See NRC dividend history and benchmarks
Is National Research undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NRC ($44.69) is trading below our estimate of fair value ($68.3)
Significantly Below Fair Value: NRC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NRC is poor value based on its PE Ratio (31.6x) compared to the US Healthcare industry average (22.4x).
PE vs Market: NRC is poor value based on its PE Ratio (31.6x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NRC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NRC is overvalued based on its PB Ratio (14.9x) compared to the US Healthcare industry average (3.2x).
How is National Research forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as National Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has National Research performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NRC has high quality earnings.
Growing Profit Margin: NRC's current net profit margins (25.6%) are lower than last year (27.8%).
Past Earnings Growth Analysis
Earnings Trend: NRC's earnings have grown by 13.8% per year over the past 5 years.
Accelerating Growth: NRC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NRC had negative earnings growth (-0.7%) over the past year, making it difficult to compare to the Healthcare industry average (32.2%).
Return on Equity
High ROE: NRC's Return on Equity (47.1%) is considered outstanding.
How is National Research's financial position?
Financial Position Analysis
Short Term Liabilities: NRC's short term assets ($67.6M) exceed its short term liabilities ($40.0M).
Long Term Liabilities: NRC's short term assets ($67.6M) exceed its long term liabilities ($35.5M).
Debt to Equity History and Analysis
Debt Level: NRC's debt to equity ratio (37.5%) is considered satisfactory.
Reducing Debt: NRC's debt to equity ratio has increased from 5.3% to 37.5% over the past 5 years.
Debt Coverage: NRC's debt is well covered by operating cash flow (182.9%).
Interest Coverage: NRC's interest payments on its debt are well covered by EBIT (27x coverage).
What is National Research current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NRC's dividend (1.07%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.3%).
High Dividend: NRC's dividend (1.07%) is low compared to the top 25% of dividend payers in the US market (3.57%).
Stability and Growth of Payments
Stable Dividend: NRC has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: NRC has only been paying a dividend for 7 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (16.9%), NRC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Hays (66 yo)
Mr. Michael D. Hays, also known as Mike, serves as an Advisor of Picker Institute Inc. Mr. Hays founded National Research Corp. in 1981 and has been its Chief Executive Officer since 1981 and has been its...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD254.50K) is below average for companies of similar size in the US market ($USD2.28M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: NRC's management team is seasoned and experienced (7.7 years average tenure).
Experienced Board: NRC's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NRC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
National Research Corporation's employee growth, exchange listings and data sources
- Name: National Research Corporation
- Ticker: NRC
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.136b
- Shares outstanding: 25.43m
- Website: https://nrchealth.com
Number of Employees
- National Research Corporation
- 1245 Q Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 22:57|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.